Peptide Comparison
ChonlutenvsLL-37
Bronchopulmonary tripeptide bioregulator (Glu-Asp-Gly) that restores respiratory epithelial function through DNA minor groove binding at ATTTC sequences, induces TNF tolerance in alveolar macrophages reducing inflammatory cytokines by up to 6-fold, and normalizes bronchial mucosa differentiation markers in aging lung tissue
Human cathelicidin-derived antimicrobial peptide (37 amino acids) that disrupts bacterial membranes at MIC 0.62 μM against S. aureus, neutralizes endotoxin (LPS) to prevent septic shock, and has reached Phase II clinical trials as Ropocamptide for wound healing — achieving 6-fold accelerated healing at 0.5 mg/mL in venous leg ulcers
At a Glance
Quick
comparison
Dose Range
Chonluten
5–10 mg
LL-37
0.5–1.6 mg/mL (topical)
Frequency
Chonluten
Once daily
LL-37
Once daily
Administration
Chonluten
Sublingual (enteric-coated capsules)
LL-37
Topical application (wound healing)
Cycle Length
Chonluten
12+ weeks
LL-37
12+ weeks
Onset Speed
Chonluten
Gradual (3-4 weeks)
LL-37
Moderate (1-2 weeks)
Evidence Level
Chonluten
Limited human trials
LL-37
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
Respiratory Tissue Repair
Lung Inflammation Control
Age-Related Lung Protection
Wound Healing
Fighting Infections
Immune Boost
Technical Data
Compound
specifications
Chonluten
Molecular Formula
C11H17N3O8
Molecular Weight
319.27 g/mol
Half-Life
Short plasma half-life typical of tripeptides (minutes to hours); biological effects persist for weeks to months through epigenetic modifications to bronchopulmonary gene expression; metabolized to constituent amino acids
Bioavailability
Absorbed via intestinal peptide transporters (PepT1) in oral formulation with enteric coating; rapid absorption from subcutaneous injection sites; efficient cellular uptake and nuclear penetration due to ultra-short tripeptide structure
CAS Number
75007-24-8
LL-37
Molecular Formula
C205H340N60O53
Molecular Weight
4,493.26 Da
Half-Life
Short systemic half-life (minutes) due to protease susceptibility; local tissue persistence at wound sites is longer due to binding to extracellular matrix components and lipid membranes
Bioavailability
Topical application achieves high local wound-bed concentrations; systemic bioavailability limited by rapid proteolytic degradation and serum protein binding; not intended for oral delivery
CAS Number
154947-66-7
Protocols
Dosing
tiers
Chonluten
LL-37
Applications
Best
suited for
Chonluten
Respiratory health restoration in aging individuals with declining lung function
Chonluten is particularly well-suited for individuals focused on respiratory health restoration in aging individuals with declining lung function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Chronic bronchopulmonary conditions requiring tissue-level regenerative support
Chonluten is particularly well-suited for individuals focused on chronic bronchopulmonary conditions requiring tissue-level regenerative support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols targeting respiratory and immune function
Chonluten is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting respiratory and immune function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Geroprotective therapy for lung tissue preservation in elderly populations
Chonluten is particularly well-suited for individuals focused on geroprotective therapy for lung tissue preservation in elderly populations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
LL-37
Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers
LL-37 is particularly well-suited for individuals focused on treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas)
LL-37 is particularly well-suited for individuals focused on immune defense against antibiotic-resistant bacterial infections (mrsa, pseudomonas). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Anti-biofilm strategies for chronic wound infections and medical device-associated infections
LL-37 is particularly well-suited for individuals focused on anti-biofilm strategies for chronic wound infections and medical device-associated infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Boosting innate immune defense in immunocompromised or aging individuals
LL-37 is particularly well-suited for individuals focused on boosting innate immune defense in immunocompromised or aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety Profile
Side
effects
Chonluten
Common
- Injection site reaction
- Mild fatigue
- Transient respiratory changes
- Mild headache
Uncommon
- Flu-like symptoms
Serious
- No documented serious adverse effects
LL-37
Common
- Local site irritation
- Transient stinging or burning
- Mild perilesional erythema
- Increased wound exudate
Uncommon
- Allergic contact reaction
Serious
- Hemolytic activity at systemic concentrations
Research Status
Safety
& evidence
Chonluten
Evidence Level
Limited human trials
FDA Status
Research compound
Safety Overview
Chonluten is a cartilage-derived peptide extract used primarily in Russian and Eastern European medicine that lacks FDA approval and rigorous clinical safety data. As a poorly defined mixture of collagen peptides and proteoglycans from cartilage tissue, standardization and batch consistency cannot be guaranteed. Potential risks include allergic reactions to connective tissue proteins, contamination from animal tissues, and unknown immunological effects from proteoglycan components. No formal safety assessments, animal toxicology studies by modern standards, or human Phase 1/2 trials exist. Long-term safety outcomes are completely unstudied.
Contraindications
- xKnown hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, glycine)
- xPregnancy and breastfeeding — insufficient reproductive safety data
- xActive pulmonary infections requiring immediate medical treatment
- xSevere immunosuppression without medical supervision — immunomodulatory effects may be unpredictable
LL-37
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
LL-37 is an endogenous cathelicidin antimicrobial peptide naturally produced by immune cells and epithelial tissues, conferring inherent biocompatibility and low toxicity at physiological concentrations. Synthetic LL-37 shows excellent safety in in vitro immune assays and animal models with no hepatotoxicity, nephrotoxicity, or genotoxicity at relevant doses. At elevated concentrations, the cationic amphipathic structure can cause hemolysis and cell membrane damage, but therapeutic doses are far below these thresholds. Injection site reactions are minimal in research applications.
Contraindications
- xKnown hypersensitivity to cathelicidin peptides or formulation components
- xActive hemolytic conditions — LL-37 demonstrates concentration-dependent hemolytic activity
- xPregnancy and breastfeeding — insufficient reproductive safety data from clinical trials
- xSevere renal impairment — peptide clearance may be altered
Decision Guide
Which is
right for you?
Choose Chonluten if...
- Respiratory health restoration in aging individuals with declining lung function
- Chronic bronchopulmonary conditions requiring tissue-level regenerative support
- Comprehensive Khavinson bioregulator protocols targeting respiratory and immune function
- Geroprotective therapy for lung tissue preservation in elderly populations
Choose LL-37 if...
- Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers
- Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas)
- Anti-biofilm strategies for chronic wound infections and medical device-associated infections
- Boosting innate immune defense in immunocompromised or aging individuals